Richardson BE, et al. - Researchers aimed at examining the observable effects of providing brincidofovir, an oral analog of cidofovir that achieves high tissue levels of the active metabolite with low systemic toxicity, on HPV-related disease of the larynx. Oral brincidofovir was provided according to protocol to two patients with laryngeal recurrent respiratory papillomatosis (one each of genotypes 6 and 11) and 1 with recurring aryepiglottic fold carcinoma in situ (genotype 16). During and after the study period, they performed close-range videoendoscopic examinations to assess disease behavior in the absence of other interventions, and after subsequent surgical intervention. Findings from this small pilot study suggest brincidofovir as effective in attenuating HPV disease of the larynx, though further investigation is necessary because the disease and potential confounding factors are highly variable in nature.